Latanoprost for Eyelash Growth — Skin & Hair
Prostaglandin F2-alpha analog primarily used for glaucoma, with off-label use for eyelash hypotrichosis based on the hypertrichosis side effect profile.
Overview
Latanoprost (Xalatan) is a prostaglandin F2-alpha analog FDA-approved for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. One of its most notable side effects — eyelash hypertrichosis (increased length, thickness, darkness, and number of lashes) — was first reported in glaucoma patients and subsequently led to the development of bimatoprost (Latisse) specifically for eyelash enhancement. While bimatoprost received FDA approval for eyelash hypotrichosis, latanoprost has been used off-label for the same indication, with multiple studies demonstrating comparable efficacy. A randomized controlled trial comparing latanoprost 0.005% to bimatoprost 0.03% applied to the upper eyelid margin showed statistically significant increases in eyelash length (2.0 mm vs 2.4 mm increase), with latanoprost producing slightly less periorbital side effects. The mechanism involves prolonging the anagen (growth) phase of the eyelash hair cycle and stimulating melanogenesis in hair follicle melanocytes. Prostaglandin analogs bind to the FP prostanoid receptor on hair follicle dermal papilla cells, activating pathways that promote hair matrix cell proliferation. Effects are visible within 4-8 weeks, with maximum growth at 12-16 weeks. Discontinuation leads to gradual return to baseline over 4-8 weeks.
Indications
- FDA-approved: Reduction of elevated intraocular pressure in open-angle glaucoma
- FDA-approved: Ocular hypertension
- Off-label: Eyelash hypotrichosis (enhancement of length, thickness, and darkness)
- Off-label: Eyebrow enhancement (applied to brow area)
- Moderate evidence: Comparable eyelash growth effects to bimatoprost
Mechanism of Action
Latanoprost acid (active metabolite) binds to FP prostanoid receptors on dermal papilla cells of hair follicles, initiating intracellular signaling
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Latanoprost ophthalmic solution | 0.005% (one drop) | Once nightly to upper eyelid margin | Apply with sterile applicator brush; blot excess |
| Latanoprost ophthalmic solution | 0.005% (one drop) | Once daily in the evening | FDA-approved glaucoma dosing — one drop per affected eye |
Evidence Grade
GRADE C
Safety & Contraindications
- Periorbital skin hyperpigmentation (darkening) — reversible upon discontinuation
- Iris pigmentation change (increased melanin) — may be permanent; rare with eyelid application
- Periorbital fat atrophy (prostaglandin-associated periorbitopathy) with chronic use
- Conjunctival hyperemia (eye redness) if solution enters the eye
- May lower IOP even when applied to lid margin — monitor if using other glaucoma medications
- Contraindicated in pregnancy (Category C); may induce uterine contractions